Mark S. Verratti's most recent trade in Myriad Genetics, Inc. was a trade of 1,069 Common Stock done at an average price of $4.9 . Disclosure was reported to the exchange on April 14, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Myriad Genetics Inc | Mark S. Verratti | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.91 per share. | 14 Apr 2026 | 1,069 | 629,646 (0%) | 0% | 4.9 | 5,249 | Common Stock |
| Myriad Genetics Inc | Mark S. Verratti | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.58 per share. | 22 Mar 2026 | 2,055 | 630,715 (0%) | 0% | 4.6 | 9,412 | Common Stock |
| Myriad Genetics Inc | Mark S. Verratti | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2026 | 247,423 | 662,059 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics Inc | Mark S. Verratti | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.66 per share. | 12 Mar 2026 | 9,164 | 652,895 (0%) | 0% | 4.7 | 42,704 | Common Stock |
| Myriad Genetics Inc | Mark S. Verratti | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.66 per share. | 12 Mar 2026 | 9,096 | 632,770 (0%) | 0% | 4.7 | 42,387 | Common Stock |
| Myriad Genetics Inc | Mark S. Verratti | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.66 per share. | 12 Mar 2026 | 5,611 | 641,866 (0%) | 0% | 4.7 | 26,147 | Common Stock |
| Myriad Genetics Inc | Mark S. Verratti | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.66 per share. | 12 Mar 2026 | 5,418 | 647,477 (0%) | 0% | 4.7 | 25,248 | Common Stock |
| Myriad Genetics Inc | Mark S. Verratti | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 32,810 | 414,636 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics Inc | Mark S. Verratti | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.77 per share. | 21 Sep 2025 | 1,085 | 381,826 (0%) | 0% | 7.8 | 8,430 | Common Stock |
| Myriad Genetics Inc | Mark S. Verratti | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 105,785 | 105,785 | - | - | Performance-Based Restricted Stock Units | |
| Myriad Genetics Inc | Mark S. Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.08 per share. | 14 Apr 2025 | 1,085 | 382,911 (0%) | 0% | 8.1 | 8,767 | Common Stock |
| Myriad Genetics Inc | Mark S. Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.01 per share. | 22 Mar 2025 | 3,623 | 386,697 (0%) | 0% | 10.0 | 36,266 | Common Stock |
| Myriad Genetics Inc | Mark S. Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.98 per share. | 22 Mar 2025 | 1,605 | 383,996 (0%) | 0% | 10.0 | 16,018 | Common Stock |
| Myriad Genetics Inc | Mark S. Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.01 per share. | 22 Mar 2025 | 1,366 | 390,320 (0%) | 0% | 10.0 | 13,674 | Common Stock |
| Myriad Genetics Inc | Mark S. Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.98 per share. | 22 Mar 2025 | 1,096 | 385,601 (0%) | 0% | 10.0 | 10,938 | Common Stock |
| Myriad Genetics Inc | Mark S. Verratti | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 99,227 | 401,262 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics Inc | Mark S. Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 5,847 | 395,415 (0%) | 0% | 10.1 | 58,879 | Common Stock |
| Myriad Genetics Inc | Mark S. Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 3,729 | 391,686 (0%) | 0% | 10.1 | 37,551 | Common Stock |
| Myriad Genetics Inc | Mark S. Verratti | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 12,758 | 302,035 (0%) | 0% | 0 | Common Stock |